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l-Deprenyl (R-( )-deprenyl, selegiline) is an inhibitor of monoamine oxidase-B (MAO-B) that is known to protect nerve cells from a
variety of chemical and physical insults. As apoptosis is a common mechanism of radiation-induced cell death, the effect of l-deprenyl
on the survival of cultured cells and tissue explants was studied following exposure to gamma radiation. The results obtained were
compared with the effects of the less-selective MAO-B inhibitor pargyline and the MAO-A inhibitor clorgyline. l-Deprenyl at a
concentration of 10
 9 M protected the nontumorigenic cell line (HaCaT) and normal human urothelial explants from the effects of
cobalt-60 gamma radiation, but did not protect tumorigenic human cell lines HaCaT-ras, HPV-transfected human keratinocytes
(HPV-G cells), or PC3. Human bladder carcinoma explants were not protected. Clorgyline showed a smaller protective effect of
normal cells, whereas pargyline had no effect. Radiation-induced delayed effects (genomic instability measured as delayed cell death)
were prevented in normal cells by l-deprenyl but, interestingly, deprenyl appeared to increase the amount of delayed death in the
tumorigenic cell lines. Studies using l-deprenyl prior to the exposure of nonmalignant cells to cisplatin showed that cell death due to
this agent was also reduced. Treatment of cultures of nontumorigenic cells with l-deprenyl or clorgyline significantly increased the
levels of the protein Bcl-2 following irradiation, but there was no such effect on the already-elevated levels of this protein in the
tumour samples. Since the Bcl-2 has been shown to be an inhibitor of apoptosis or programmed cell death, this would imply that the
protective effects of l-deprenyl and clorgyline involve activation of antiapoptotic pathways within the normal cell. This hypothesis is
supported by data showing reduced levels of apoptosis in HaCAT cells and in normal bladder explant cultures following treatment
with l-deprenyl.
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Protection of normal tissues from damage during radiotherapy is a
key goal of experimental radiotherapy and a key problem in
patient treatment. Most chemical approaches aim to sensitise the
tumour, but it is equally valid to seek radioprotective drugs which
will selectively protect the normal cells. As an approach to this, our
group looked at agents already in clinical use, which aim to reduce
or prevent death or damage of cells during degenerative disease
processes. In this paper, we report results using monoaimine
oxidase inhibitors. Since the biochemistry of these and their
function in protecting cells against death is unlikely to be familiar
to oncology specialists, the background is reviewed somewhat
extensively in this introduction.
Monoamine oxidase (EC 1.4.3.4; MAO) enzymes catalyse the
oxidative deamination of a range of monoamines, including the
catecholamines and serotonin. The enzyme exists in two forms,
MAO-A and MAO-B (for reviews, see Yu, 1986; O’Brien and
Tipton, 1994), which are encoded by distinct gene loci on the X-
chromosome (Shih, 1991).
l-Deprenyl (R-( )-deprenyl, selegiline, eldepryl) is an irrever-
sible inhibitor of MAO-B, which has been used as an adjunct to
reduce the oxidation of dopamine, in the L-DOPA-treatment of
Parkinson’s disease (see Birkmayer et al, 1975). L-deprenyl has
been shown to protect against neuronal damage resulting from
other chemical and physical insults, and it was suggested that the
actions of this compound might be better described as neuronal
rescue rather than neuronal protection (Salo and Tatton, 1991;
Tatton and Greenwood, 1991). The mechanisms involved of this
neurorescue effect are unclear. l-Deprenyl, and some other MAO-B
inhibitors, bind to the apoptosis-regulating protein glyceralde-
hyde-3-phosphate dehydrogenase (Kragten et al, 1998), and also
stimulate the expression of a number of antiapoptotic gene
products (see Tatton et al, 2002), as well as the amine synthesis
enzyme L-aromatic amino-acid decarboxylase (Li et al, 1992). l-
Deprenyl at concentrations too low to inhibit MAO-B (o10
 9 M)
prevents PC12 cells from undergoing apoptosis induced by trophic
factor withdrawal in a process that requires new protein synthesis
(Tatton et al, 1994a,b). This has led to the suggestion that l-
deprenyl conveys its protective effects via the activation of
antiapoptosis pathways within the cell, and that this neuroprotec-
tion is independent of MAO-B inhibition.
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sl-Deprenyl may be involved in regulation of the cell cycle, where it
could possibly prevent the senescence of astroglial cells, which
presumably act by providing trophic factor support to the nerve cells
(Shimazu et al, 1993). Among the other neuroprotective mechanisms
that have been proposed are an antioxidant effect (Chiueh et al, 1994)
and the preservation of mitochondrial membrane potential, and an
associated inhibition of mitochondrial permeability-transition pore
opening (see Wadia et al, 1998; Zhang et al, 1999). Although studies
in relation to the protective effects of l-deprenyl have concentrated
on nerve cells or related systems, such as dopaminergic PC12 cells
(Tatton et al, 1994a,b), there appeared to be no ap r i o r ireason to
believe that its protective or rescue effects might not be more general.
In order to investigate such a possibility, we have investigated the
effects of l-deprenyl, pargyline and clorgyline on the survival of
cultured cells and tissues following exposure to g-radiation from a
radiotherapeutic cobalt-60 (Co-60) source.
EXPERIMENTAL METHODS
Cell lines and culture conditions
Four cell lines were used in this study. Wild-type HaCaT are
considered to be immortal but nonmalignant; HPV-G, HaCaT-ras
and PC3 cells are generally considered to be tumorigenic. HaCaT-
ras and PC3 form malignant tumours in immune-suppressed mice
and HPV-G cells form benign nodules. The HaCaT cell line is a
normal human keratinocyte cell line derived from human skin
keratinocytes spontaneously transformed in vitro during long-
term incubation of a primary culture under selected culture
conditions (Boukamp et al, 1999). It was obtained as a kind gift
from Dr P Boukamp (DKFZ, Heidelberg University, Germany),
who also supplied us with the H-ras-transfected variant of HaCaT
cells. The HPV-G cell line is a human immortal keratinocyte cell
line that was derived from human neonatal foreskin transfected
with the HPV-16 virus in order to cause immortalisation (Pirisi
et al, 1987). It was obtained as a kind gift from Dr J Dipaolo (NIH,
Bethesda, MD, USA). The PC3 cell line is a human prostate
adenocarcinoma cell line established from a grade 4 prostatic
adenocarcinoma from a 62-year-old male Caucasian, and was
obtained from the European collection of cell cultures (ECACC). All
the cell lines were maintained at 371C in Dulbecco’s MEM: Ham’s
nutrient mixture (F12) 1:1 (Gibco Biocult, UK) supplemented with
10% foetal calf serum, 50IUml
 1 penicillin, 50mgml
 1 streptomy-
cin solution, 2mML -glutamine, 1mg hydrocortisone and 12.5ml
HEPES buffer (1 M), all from Gibco Biocult, UK.
Assay of cell survival and frequency of lethal mutations
(delayed cell death)
The standard clonogenic assay (Puck and Marcus, 1956) with the
lethal mutation extension (Seymour et al, 1986) was used for all
cell lines. A healthy confluent flask of cells was trypsinised using
0.25% wv
 1 trypsin solution and 1mM versene solution in a 1:1
mixture. The resulting cell suspension was counted using a Coulter
counter (Corning model Dn). Appropriate cell numbers were then
plated in 5ml of culture medium. At the appropriate times post
irradiation when the irradiated cells produced colonies containing
approximately 200 cells, half of the cultures were stained with
carbol fuchsin (Ziehl Nielson 1:15). The number of macroscopic
colonies was counted and the initial radiation survival determined.
The rest of the cultures were grown to confluence, subcultured and
replated without further irradiation to measure delayed cell death
(lethal mutations) in the progeny.
Explant culture technique
Biopsies of normal urothelium were obtained from patients
undergoing reconstructive or investigative surgery for benign
conditions. These were set up as explants, using the techniques
described by Mothersill et al (1988). Bladder tumour biopsies were
obtained during clinical investigations for suspected malignancy.
The malignant nature of these biopsies was subsequently
confirmed by the histopathology. All were confirmed as low-grade
transitional cell carcinomas (TCC). The tissue was placed in sterile
physiological saline immediately upon removal from the patient,
and placed in a refrigerator until it could be processed. Cultures
were normally established within 6h, although growth was
achieved successfully even after 24h storage at 41C. The biopsies
were divided into approximately four explant-sized pieces, and
were then transferred into 0.25% wv
 1 trypsin solution (Gibco
Biocult, UK) containing 10mgml
 1 collagenase type IV (Sigma,
USA) and incubated for 30min at 371C. After this, the partially
digested pieces were plated individually as explants in 25cm
2 40-ml
volume tissue culture flasks containing 2ml RPMI 1640 medium
(Gibco Biocult, UK), supplemented with 7% foetal calf serum, 3%
horse serum, 5ml 100  penicillin/streptomycin solution (all from
Gibco Biocult, UK), 1mgml
 1 hydrocortisone (Sigma), 0.1ngml
 1
epidermal growth factor (Sigma) and 100IUml
 1 insulin (Actrapid
Novo Nordisk, Denmark). When the explants had attached, usually
within 2–3 days, the cultures were transferred into Clonetics
Keratinocyte Growth medium (Clonetics Corp., San Diego, CA,
USA). This medium is a serum-free formulation containing insulin,
hydrocortisone, epidermal growth factor, bovine pituitary extract
and the antibiotics, ampicillin and gentamycin. Cultures were
maintained in this medium with no medium changes for 2–3 weeks
(Mothersill et al, 1995). The tumour biopsy material was processed
using the same method.
Monoamine oxidase inhibitors (MAOIs)
l-Deprenyl was obtained from Semat Technical Ltd (St Albans,
Herts, UK) and clorgyline (N-methyl-N-propargyl-3-(2,4-dichlor-
ophenoxy)-propylamine hydrochloride) and pargyline (N-methyl-
N-2-propynylbenzylamine hydrochloride) were both supplied by
Sigma. All MAOIs were made up to the desired concentrations in
deionised water and were administered to each cell or explant
culture 6h prior to irradiation. The concentrations of MAOIs
used ranged from 10
 11 to 10
 3 M. The concentration used for
neurorescue in the clinic is 10
 9 M. The volume of MAOI added to
each cell or explant culture was always 100ml. In the control
cultures, where no MAOI was added, 100ml of deionised water was
added instead of the MAOI, in order to keep the volume of cell
culture medium constant throughout the experiment.
Irradiation
Cultures of cell lines were treated 8h after plating. Explants were
irradiated 3 days after plating and after transfer into serum-free
medium. Irradiation was performed at room temperature using a
Co-60 teletherapy unit delivering approximately 1.8Gymin
 1 at
80cm source-to-flask distance. The doses chosen were 0.5 and
5Gy. All treated flasks and sham-irradiated controls were returned
immediately to the CO2 incubator and left undisturbed for 9 days
to allow colony formation. Cell lines were generally stained with
carbol fuchsin for assessment of clonogenic survival but, in some
cases, colonies were fixed in 10% unbuffered formalin to allow
immunocytochemical investigations to be done. Explant cultures
were maintained for 2 weeks and then fixed with formalin and
studied using immunocytochemistry.
Immunocytochemistry
At appropriate times (9 days for the cell lines or 2 weeks for the
explants), cultures were fixed in formalin for 24h, then stored in
PBS at 41C for not more than 1 week before staining. The plastic
flasks were then cracked open using pliers and the explant culture,
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sor cell line clones were processed on the flask base as for
specimens mounted on glass slides. This method preserved the
spatial organisation and distribution of the staining in the culture.
Immunostaining was performed using Vectastain ABC
s kits
(Vectastain Corp, Burlingame, CA, USA) with diaminobenzidine
(DAB) as the chromogen. The primary antibody used to detect Bcl-
2 expression was the anti-Bcl-2 antibody (DAKO Laboratories,
Bucks, UK). This antibody was divided into aliquots on receipt and
stored at  201C until required. Positive and negative controls were
run with each batch of cultures. The positive control for Bcl-2
expression consisted of a Bcl-2-positive lymphoma section.
Negative controls routinely included with each run were the same
cell lines or explants run with no primary antibody. In all cases,
cultures were counterstained using Mayer’s haematoxylin.
Quantification of Bcl-2 protein expression
The expression of Bcl-2 was quantified in the cultures using image
analysis (Leica system). The fields for analysis were chosen along
two transects drawn at right angles to each other across the explant
culture. This method ensured that any differences between cells at
the centre and edge of the explant were accounted for, and that any
evidence of clonal expression originating from specific irradiated
cells would be identified. A cell was designated as positive if the
staining was equal to or greater than the positive control. The cell
number was determined by measuring the area of the explant
outgrowth and the number of cells in 10 replicate 1mm
2 sample
areas chosen at random from the culture. For cell lines, positive
cells were counted in 10 randomly chosen clones at 7–9 days
postirradiation or in 100 randomly chosen microcolonies, where
48h data were being collected. In each case, counts were made in
each of three replicate cultures and expressed as a function of the
total cells counted in the clone or microcolony.
Measurement of apoptosis in explant cultures and in
HaCaT microcolonies
Apoptosis was scored in the explant outgrowth cultures by
counting the numbers of apoptotic cells in 10 randomly chosen
100m
2 fields at 30min before, and at 48h and 14 days
postirradiation. Identification of apoptotic cells was performed
using the criteria defined in Lyng et al (2002) and the results were
confirmed using electron microscopy.
In the clonogenic cell lines (HaCaT and HaCAT-ras), micro-
colonies were examined at 48h postexposure to irradiation for
signs of apoptosis. In all, 100 microcolonies per dish were scored
and the total apoptotic cells over total cells counted was expressed
as a percentage. Previous data from our group have validated these
methods (Mothersill et al, 1995).
Statistical analysis
All experiments were repeated three independent times. Within
each experiment, assays were set up in triplicate. The results are
the mean7s.e.m. for the three independent experiments. Sig-
nificance was assessed using the Student’s t-test.
RESULTS
Effects of MAOIs on the relative cell survival of normal
uroepithelial and bladder tumour explants exposed to Co-
60 c radiation
Figure 1 shows the effect of deprenyl, at a concentration of 10
 9 M,
on the survival of normal human urothelial explants exposed to 0,
0.5 or 5Gy of Co-60 gamma radiation; l-deprenyl caused a
significant increase in survival after 0.5 and 5Gy.
The effect of l-deprenyl on human bladder tumour explants
exposed to 0, 0.5 and 5Gy of Co-60 g radiation is also shown in
Figure 1. At all radiation doses examined, l-deprenyl at a
concentration of 10
 9 M, which was radioprotective for normal
tissue explants, showed no radioprotective effect for tumour
explants. In contrast, there is a trend for tumour explants to be
sensitised by exposure to l-deprenyl, although this is only
statistically significant at the 0.5Gy dose.
Effects of l-deprenyl and clorgyline on the initial radiation
survival of four cell lines, exposed to Co-60 c radiation
Table 1 shows the initial radiation survival of the four cell lines,
HaCaT, HaCaT-ras, HPV-G and PC3 cell lines, exposed to 0, 0.5 or
5Gy of Co-60 g radiation with l-deprenyl or clorgyline at
concentrations of 10
 9 M, which is the concentration used in the
clinic. The results show that l-deprenyl acted as an effective
radioprotector for HaCaT cells irradiated to 0.5 or 5Gy. In some
experiments, higher concentrations of l-deprenyl were tested. The
radioprotective effect was significantly (Po0.05) greater after
10
 9 M than after 10
 5 M l-deprenyl (data not shown). Clorgyline at
a concentration of 10
 9 M also acted as an effective radioprotective
compound at these radiation doses. Examination of the control PE
data in the presence of these agents shows that the plating
efficiency of the cells is higher, suggesting that death of cells is
reduced even in the absence of radiation. It is also apparent on
analysis of the data that the radioprotective effect is increased with
increasing dose. That is, the greater the radiation dose, the greater
the radioprotective effect.
With HPV-G cells, which have compromised but wild-type p53
due to the presence of the E6 protein of the HPV virus, l-deprenyl
or clorgyline at a concentration of 10
 9 M produced no radio-
protective effect at either 0.5 or 5Gy doses. The data for the PC3
human prostate carcinoma cell line also demonstrate the absence
of l-deprenyl-induced radioprotection in a tumour cell line.
Figure 2 shows clonogenic survival data for HaCaT cells and the
H-ras-transfected variant exposed to a range of l-deprenyl
concentrations (10
 5–10
 11 M) prior to a range of radiation doses
(0.5–5Gy). There were no protective effects of l-deprenyl using the
ras-transformed line, whereas protection was observed with the
Figure 1 Effects of pretreatment with 1nM l-deprenyl on the radiation
response of human normal and malignant bladder explants. The area of the
outgrowth was measured on day 14 postirradiation and the treated
outgrowth area is expressed as a percentage of the control (mean7s.e.m.
for five patients per group). Absolute values for the normal control were
4607120mm
2 and for the tumour 246760mm
2.* Po0.05, **Po0.01.
Radioprotective effects of l-deprenyl
CB Seymour et al
1981
British Journal of Cancer (2003) 89(10), 1979–1986 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
snormal line. The l-deprenyl dose–response for the normal
keratinocytes was stable at doses lower or equal to 10
 5 M. A high
1m M dose was also tested, but was toxic, and, as no colonies
formed, the data were excluded from the figure.
Effects of l-deprenyl and clorgyline on induction of lethal
mutations (delayed reproductive death)
Table 2 shows the effect of l-deprenyl on induction of delayed cell
death/lethal mutations in progeny of cells exposed to irradiation.
HaCaT, HaCaT-ras and HPV-G were exposed to 0, 0.5 or 5Gy of
Co-60 gamma radiation with l-deprenyl or clorgyline at a
concentration of 10
 9 M. The exposed cells were grown to
confluence and then subcultured without further treatment with
radiation, and without further addition of l-deprenyl to the cells.
The survival of the progeny was examined after at least 15
population doublings. The values for plating efficiency below 100%
show that delayed cell death is occurring. The values above 100%
are associated with protection from delayed death or proliferation-
stimulating delayed effects. l-Deprenyl or clorgyline treatment of
HaCaT progenitor cells prior to irradiation protected progeny cells
originally irradiated at 0.5Gy from delayed death. When the
progenitor cultures were treated with 10
 9 M l-deprenyl and then
irradiated to 5Gy, the progeny of the irradiated cells shows a large
antidelayed death radioprotective effect. Clorgyline also protected
progeny cells; however, this protective effect was less than that
found with l-deprenyl. Data for the tumorigenic cell lines show
much less protection either with l-deprenyl or clorgyline in
cultures irradiated to 0.5 or 5Gy. In fact, the survival of l-deprenyl-
or clorgyline-treated tumour cell line progeny was significantly
decreased by the treatment alone (Po0.01).
Effects of l-deprenyl on survival of HaCaT and HaCaT-ras
cells treated with cisplatin
Most cancer therapy involves chemotherapy as well as, or instead
of, radiotherapy; therefore experiments were done to determine
whether l-deprenyl could protect normal cells from cisplatin
toxicity. The data for the normal HaCaT cells are shown in Figure 3.
Clearly, l-deprenyl can protect normal cells from cisplatin toxicity.
HaCaT-ras cells showed no protection from toxicity attributable to
l-deprenyl. This effect again appears to be mainly due to the
enhanced clonogenic survival of the control cells following
deprenyl treatment, rather than to the active prevention of
cisplatin toxicity.
Expression of Bcl-2 protein and apoptosis
Figure 4A shows Bcl-2 protein expression in primary normal and
tumour explant cultures at the end of the experiment (generally 14
Table 1 Effects of l-deprenyl (D) and clorgyline (C) on the survival of four clonogenic cell lines
Plating efficiency (% of control)
Radiation dose (Gy) MAOI HaCaT cells HaCaT-ras cells HPV-G cells PC3 cells
0 0 100 (28.672.5) 100 (56.774.4) 100 (23.472.1) 100 (11.971.3)
0.5 0 81.375.4 10075.2 65.773.3 80.473.4
5 0 17.471.1 20.673.3 19.971.7 17.571.2
0 D 15473.8 11273.1 12073.8 10275.6
0.5 D 16573.5 9875.2 10374.8 89.277.7
5D 8 2 74.9 17.973.7 21.072.1 20.473.6
0 C 17075.7 90.174.0 97.572.7 96.672.7
0.5 C 14976.6 77.373.5 99.273.7 75.174.8
5 C 79.074.3 12.573.4 20.071.7 19.072.3
All cell lines were set up in a medium containing the indicated monoamine oxidase inhibitor (MAOI) at a concentration of 1nm and irradiated 6h later. All plating efficiencies are
expressed relative to the control, which received no radiation, D or C.
Figure 2 Effects of varying concentrations of l-deprenyl and varying radiation doses on the % of HaCaT or HaCaT-ras cell colonies surviving treatment.
Cells were plated in medium containing 1nM l-deprenyl and irradiated 6h later. Absolute control plating efficiency values were 34.572.7 for HaCaT cells
and 56.773.7 for HaCaT-ras cells.
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sdays) postirradiation, detected using immunocytochemistry. This
technique was used in preference to Western blotting, because of
the very small numbers of cells which grow from primary explants
and because immunocytochemistry allows spatial information to
be retained and permitted us to quantify the numbers of cells
expressing the protein. Owing to the small numbers of explants
available from human tissue biopsies, it was not possible to study
Bcl-2 expression during the growth period; however, the apoptosis
data described in the next section were obtained by noninvasive
methods. Treatment with l-deprenyl or clorgyline resulted in
increased Bcl-2 expression in the normal human uroepithelial
explants in all circumstances. In the bladder carcinoma explants,
Bcl-2 expression was found to be 100% positive both in the
presence and absence of l-deprenyl or clorgyline. Figure 4B shows
the levels of apoptotic cells in explant cultures before being treated
with 0.5 or 5Gy Co-60 g-rays, at 48h afterwards and at the end of
the experiment. The results show that preirradiation, there are
only very low levels of apoptotic cells in the explant cultures. After
48h, the level in the irradiated cells rises significantly in the
radiation-only group, but remains significantly lower in the
deprenyl-treated group. By the time the cultures are fixed at the
end of 14 days in the explant system, the detectable levels of
apoptosis have fallen but are still higher than the preirradiation
level. Some experiments were done to assess effects on BAX and
p53 protein expression.
Table 3 shows data for the HaCaT cell line. Clearly, treatment
with l-deprenyl leads to increased post irradiation expression of
Bcl-2 in the normal cell line. In the HaCaT-ras cells, Bcl-2 was
expressed in all cells in all microcolonies at 48h and at 9 days
postirradiation. l-Deprenyl treatment had no further effect (data
not shown). In the other cell lines, expression of Bcl-2, measured at
7–9 days after irradiation, was also already elevated in all cells in
all the cultures and neither l-deprenyl nor clorgyline treatment had
any further effect (data not shown).
In order to test the hypothesis that Bcl-2 expression was directly
linked to the suppression of apoptosis, experiments were done
with HaCaT cells where cultures were fixed at 48h and 7–9 days
postirradiation. Apoptosis and Bcl-2 expression were then
measured in the same microcolony or colony.
Immunocytochemistry was the method of choice in the cell line
studies because, in order to perform clonogenic assays, only small
numbers of cells can be inserted into a flask (100–500). Also, by
retaining spatial information concerning the multiplicity of the
microcolony, the data can be used to correlate apoptotic scores
with Bcl-2 scores directly and in relation to microcolony size (a
good indicator of likely survival). It is now recognised by our
group that in order to correlate data concerning apoptosis and
Bcl-2 expression, similar cell number:medium volumes must be
used. If they are not, the results are influenced by neighbour effects
involving signalling and energy substrate concentrations. There-
fore, extreme care was taken to measure apoptosis and Bcl-2 in
similarly seeded cultures. Measurements were done at 48h when
apoptosis was measured and at 7–9 days when reproductive
survival was determined.
The results that are shown in Figure 5A and B and Table 4
confirm that Bcl-2 levels were elevated after 48h (Figure 5) and
also after 7–9 days (Table 4), when the normal cells were exposed
to l-deprenyl. Clorgyline produced a similar effect (data not
shown). In Figure 5A and B, data are also presented to show the
frequency of apoptosis and Bcl-2 expression in the same
microcolonies 48h after exposure to 0.5 or 5Gy with (Figure 5B)
or without (Figure 5A) l-deprenyl. Microcolonies are grouped
according to the number of cells in the microcolony. Clearly,
apoptosis and smaller microcolony size dominate in the untreated
group and Bcl-2 expression together with larger microcolony size
dominate in the treated group. Data for the HaCaT-ras cell line
were also obtained and there was no apoptosis in any of the
cultures with or without treatment.
Table 2 Delayed reproductive death (clonogenic survival of subcultured cells) in distant progeny of cells whose progenitors were exposed to 1nm l-
deprenyl or 1nm clorgyline
Survival of progeny (% of control)
Radiation dose (Gy) MAOI HaCaT cells HaCaT-ras cells HPV-G cells
Control 0 None 100 (27.073.1) 100 (96.173.3) 100 (16.071.1)
Control 0.5 None 100 (22.272.7) 100 (57.273.9) 100 (1170.6)
Control 5.0 None 100 (6.570.4) 100 (57.972.9) 100 (1070.4)
0 l-Deprenyl 13877.3 60.074.1 12078.9
0.5 l-Deprenyl 12776.4 120710.3 19670.7
5.0 l-Deprenyl 200713.1 90.173.7 126.376.7
0 Clorgyline 10475.4 64.372.8 75.673.4
0.5 Clorgyline 12373.8 11077.1 11678.2
5.0 Clorgyline 13376.1 90.672.8 12677.7
The clonogenic assay was performed on cultures that had undergone at least 15 population doublings postexposure.
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Figure 3 Clonogenic survival for HaCaT and HaCaT-ras cells treated
with cisplatin (mgml
 1) for 1h. Cells were plated in medium containing
1n M l-deprenyl and exposed to cisplatin 16h later. Absolute control plating
efficiencies were 23.671.3 for HaCaT cells and 52.272.1 for HaCaT-ras
cells.
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sDISCUSSION
Both l-deprenyl and, to a somewhat lesser extent, clorgyline at a
concentration of 1nM had relatively large radioprotective effects
on normal cells and tissues, but did not protect tumour cells to any
significant extent. In normal clonogenic cells, where it was possible
to study delayed reproductive death in the progeny, the effects of
both MAO inhibitors was to prevent delayed death in progeny,
with clorgyline being slightly less effective This indicates that l-
deprenyl acts as a genome-stabilising agent. To our knowledge,
this is the first report of a radioprotective agent that can prevent
one of the manifestations of genomic instability.
Since exposure to l-deprenyl protected the normal uroepithelial
explants and also resulted in significant increases in Bcl-2 protein
induction, it is possible that l-deprenyl protects these normal
human uroepithelial explants via the expression of this protein.
Bcl-2 has been widely documented as an inhibitor of the apoptotic
cascade (see Sentman et al, 1991).
Of the four irradiated cell lines studied in this work, Bcl-2
protein expression was induced by both l-deprenyl and, to a lesser
extent, clorgyline in the normal HaCaT cell line. The more
abnormal cell lines studied (HPV-G, CHO-K1 and PC3) were found
to have Bcl-2 protein expression elevated to 100%. Thus, one
action of l-deprenyl and clorgyline may be to induce this
antiapoptotic pathway in the, relatively radiosensitive, normal
cells. Tumour cells generally have Bcl-2 already induced, thus
increasing their resistance to damage. It is interesting though to
note that the antiapoptotic action of deprenyl is not the only
mechanism of protection. The data in Table 1 clearly show that at
5Gy the surviving fraction of all the cell lines whether normal or
tumour is approximately 20% without l-deprenyl. This increases in
the normal cell line, but not in the tumour lines after l-deprenyl
treatment. Since Bcl-2 is maximally elevated in the tumour lines
and induced in the normal line, the action of l-deprenyl cannot be
100
75
50
25
0
0
0.5 5
Radiation dose (Gy) 
C
e
l
l
s
 
e
x
p
r
e
s
s
i
n
g
 
B
c
l
-
2
 
(
%
 
o
f
 
t
o
t
a
l
)
No addition Plus deprenyl Plus  clorgyline
30
20
10
0
01 4 2
Time (day)
A
p
o
p
t
o
t
i
c
 
c
e
l
l
s
 
(
%
)
0 Gy
0 Gy + deprenyl 0.5 Gy + deprenyl 5 Gy + deprenyl
0.5 Gy 5 Gy
A
B
Figure 4 (A) Expression of Bcl-2 protein in normal human uroepithelial
explants, treated as indicated with 1nM l-deprenyl or clorgyline. The values
for the tumour samples were all 100%, and are not shown. (B) Apoptosis
postirradiation in primary urothelial cultures treated with l-deprenyl. Data
are mean percent counts of apoptotic cells in 10 randomly selected fields
per culture.
Table 3 Effects of monoamine oxidase inhibitors and irradiation on Bcl-2
protein expression in initially irradiated cultures of HaCaT cells treated as
indicated
Radiation dose (Gy) MAOI % Positive HaCaT cells
0 None 0
01 n m l-Deprenyl 100
01 0 mm l-Deprenyl 49712
01 n m Clorgyline 5678
0.5 None 1274
0.5 1nm l-Deprenyl 100
0.5 10mm l-Deprenyl 79715
0.5 1nm Clorgyline 69711
5.0 None 58713
5.0 1nm l-Deprenyl 100
5.0 10mm l-Deprenyl 100
5.0 1nm Clorgyline 100
Table 4 Apoptosis postirradiation in colonies or potential colonies of HaCaT cells treated with l-deprenyl (mean percent apoptotic cells averaged over
100 colonies or potential colonies)
Preirradiation 48h Postirradiation 9 Days postirradiation
Treatment Cells per colony Apoptosis% Cells per colony Apoptosis% Cells per colony Apoptosis%
0Gy control 1 0 3.670.12 0.270.03 268732 0.2470.03
0.5Gy 1 0 1.170.14 25.674.6 165716 2.1570.34
5Gy 1 0 1.470.19 32.172.9 126713 2.9370.8
0Gy+10
 9 m l-deprenyl 1 3.770.08 0.170.008 374730 1.170.07
0.5Gy+10
 9 m l-deprenyl 1 0 3.270.41 0.2470.04 321735 0.8670.05
5Gy+10
 9 m l-deprenyl 1 0 2.671.1 1.2270.3 274719 0.7570.06
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when the apoptosis scores at 2 and 9 days are examined, it can be
seen that apoptosis is not as significantly elevated in any of the cell
lines after 9 days growth in culture. It is likely that the late effect of
deprenyl on the 5Gy irradiated cells represents a different
protective mechanism to that seen after 2 days. Perhaps, it is akin
to the ‘neurorescue’ seen after l-deprenyl treatment of neuronal
cells referred to in the first section. Whatever the mechanisms,
these monoamine oxidase inhibitors might prove useful in
protecting normal cells from therapeutic radiography in cancer
patients. In this context, it is noteworthy that nontumorigenic cell
lines, such as the normal HaCaT cells, normally give a relatively
low plating efficiency under culture conditions, but this is
significantly increased by exposure to l-deprenyl, presumably as
a consequence of the induction of Bcl-2.
The compounds tested in this work were all MAO inhibitors and
other propargylamine-derived MAO inhibitors, such as rasagiline
(N-propargyl-[1R]-aminoindan) and N-(2-heptyl)-N-propargyla-
mine (see Finberg et al, 1999; Huang et al, 1999; Maruyama et al,
2001) have also been shown to be neuroprotective. However, the
propargylamine derivative CGP 3466 [dibenzo[b,f]oxepin-10-
ylmethyl-methyl-prop-2-ynyl-amine], which is about 100 times
more potent than l-deprenyl as a neuroprotective or neurorescuing
agent is essentially devoid of inhibitory activity towards MAO
(Kragten et al, 1998). The lack of any radioprotective effects of the
MAO inhibitor pargyline would be consistent with the conclusion
of others that neuroprotection is a distinct phenomenon from
MAO inhibition (see eg Tatton et al, 1994a,b; Kragten et al, 1998).
Although the propargylamine moiety might be responsible for the
protection afforded by clorgyline and l-deprenyl, the lack of any
protective effect of pargyline in our system and in some other
neuronal models (see Mytilineou et al, 1997) would indicate it not
to be a general property of all propargylamine derivatives.
The possibility that factors other than the induction of Bcl-2,
which can itself prevent apoptosis in response to a number of toxic
stimuli (Sentman et al, 1991), may contribute to the radio-
protective effects of l-deprenyl and clorgyline requires considera-
tion. A proportion of the cellular Bcl-2 protein is associated with
the mitochondrial outer membrane (Krajewski et al, 1993) and the
clorgyline- and l-deprenyl-sensitive monoamine oxidases A and B,
respectively, are similarly located. Hydrogen peroxide is a product
of the oxidative deamination of amines by MAO, and this may act
as a potential source of toxic reactive-oxygen radicals (see, for
example, Sandri et al, 1990). Regulation of mitochondrial and/or
cytosolic reactive oxygen species (ROS) levels in mammalian cells
might be mediated, in part, by the bcl-2 gene product (Hockenbery
et al, 1993). Expression of the Bcl-2 protein prevents the induction
of apoptosis by a variety of oxidative stresses, including ionising
radiation, heat shock or inhibition of glutathione synthesis
(Hockenbery et al, 1990; Zhong et al, 1993). It has been suggested
that the bcl-2 gene product inhibits apoptosis by interacting with
mitochondrial superoxide dismutase (SOD) (Itoh et al, 1993).
Furthermore, it has been shown that various antioxidant agents
(eg, N-acetylcysteine and glutathione peroxidase) can substitute
for Bcl-2 expression in preventing factor-deprived cells from
undergoing apoptosis (Hockenbery et al, 1993). It is, therefore,
possible that the enhanced susceptibility to apoptosis that is
observed in the absence of Bcl-2 expression might reflect the
inability of the cell to cope with oxidative stress. Cobalt-60 gamma
radiation causes the production of ROS via the radiolytic attack of
water molecules and, since Bcl-2 has been implicated in inhibiting
apoptosis by mechanisms that may involve SOD (Itoh et al, 1993),
thereby rendering these species harmless, l-deprenyl and clorgy-
line could elicit their radioprotective effects via such mechanisms.
Indeed, it has been reported that l-deprenyl increases the activity
of cytoplasmic Cu/Zn-SOD, mitochondrial Mn-SOD and catalase
in mouse brain (see Thiffault et al, 1995). However, this
mechanism is implausible because of the efficacy of very low
doses of deprenyl and clorgyline and the lack of an increase in
effect with MAOI dose.
The most likely and very interesting explanation is that these
MAOIs interfere with the induction or transmission of genomic
instability in cells. Genomic instability is known to involve a
persistent increase in cellular oxidative stress, and to be associated
with irradiation of normal cells (reviewed in Mothersill and
Seymour, 2001). Such a mechanism would explain the ability of
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Figure 5 Expression of apoptosis (A) and bcl-2 (B) in HaCaT cells with
and without l-deprenyl treatment prior to irradiation. Cultures were all
seeded with 400 cells and were fixed at 48h postirradiation to 0, 0.5 or
5Gy Co-60 gamma rays. Apoptosis and Bcl-2 expression were scored in
the same microcolonies. In all, 20 microcolonies were scored for each
culture. Five replicate cultures were counted. Data were pooled due to low
frequency of the end points. The figures show the relative frequency of
apoptotic and Bcl-2-positive cells in the microcolonies. Open symbols, solid
lines:   deprenyl; Closed symbols, broken lines: þ deprenyl. Cells per
microcolony: 1 (&, ’); 2 (J, K); 3 (B, E); 4 (n, m).
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sl-deprenyl to reduce delayed reproductive death (lethal muta-
tions), shown in Table 2.
To summarise, l-deprenyl and clorgyline show clear evidence in
vitro of radioprotection of normal cell lines and normal tissue
explants. The mechanisms are not wholly clear, but evidence is
presented for one early mechanism operating via an antiapoptotic
pathway involving bcl-2 induction in normal cells and tissues. A
second mechanism may become important at higher doses and late
time points.
These agents may be worthy of further consideration as
radioprotective agents for normal tissue in the clinic.
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